Age as an independent predictor of progression-free survival in patients with epidermal growth factor receptor-mutant lung adenocarcinoma: a real-world retrospective study
10.3760/cma.j.issn.0254-9026.2025.11.009
- VernacularTitle:年龄是表皮生长因子受体突变肺腺癌患者无进展生存期的独立预测因素：一项真实世界回顾性研究
- Author:
Qianqian DONG
1
;
Qingqing DING
1
Author Information
1. 南京医科大学第一附属医院老年肿瘤科，南京 210029
- Publication Type:Journal Article
- Keywords:
Lung adenocarcinoma;
Epidermal growth factor receptor;
Progression free survival
- From:
Chinese Journal of Geriatrics
2025;44(11):1529-1535
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical characteristics and independent predictors of progression-free survival (PFS)in patients with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma in the real world.Methods:This was a retrospective observational study.The clinical data of 74 EGFR mutation-positive lung adenocarcinoma patients who visited the Geriatric Oncology Department of the Fisrt Affiliated Hospital of Nanjing Medical University from January 2020 to March 2025 were retrospectively collected.Retrospective analysis was performed on baseline clinical characteristics(gender, age, smoking history, stage, etc.), EGFR mutation types, and treatment follow-up data(PFS, treatment regimens). Descriptive statistics were used to summarize the baseline clinical characteristics of the patients.The distribution differences in clinical characteristics between the elderly group and the non-elderly group were compared.Kaplan-Meier survival curves were plotted with Log-rank test, and the Cox proportional hazards model was used to screen for independent prognostic factors.Results:The incidence of comorbidities in the elderly group(48.78%, 20/41)was significantly higher than that in the non-elderly group(24.24%, 8/33), with a statistically significant difference( χ2=4.681, P=0.031). No statistically significant differences were observed between groups in other variables[gender, stage, presence of multiple metastases, smoking history, Eastern cooperative oncology group (ECOG)score, treatment regimens, mutation types](all P>0.05). The median PFS (mPFS)in the elderly group was significantly shorter than that in the non-elderly group(18.20 months vs.26.78 months, Log-rank χ2=3.930, P=0.047). No significant differences in mPFS were found among gender, stage, presence of multiple metastases, smoking history, comorbidity status, ECOG score, treatment regimens, EGFR mutation types or types of tyrosine kinase inhibitor(TKI)(all P>0.05). Multivariate Cox regression further confirmed that advanced age(≥65 years)is an independent predictor of shortened PFS( HR=2.67, 95% CI: 1.04~6.85, P=0.041). The overall incidence of TKI treatment-related adverse reactions was 40.58%(28/69), with a grade ≥3 adverse event rate of 11.59%(8/69). Common adverse reactions included rash, oral mucositis, and diarrhea.The incidence of TKI-related adverse reactions in the elderly group(17/39, 43.59%)was higher than that in the non-elderly group(11/30, 36.67%), but the difference was not statistically significant( χ2=1.038, P=0.196). Conclusions:Age is an independent predictor of PFS in patients with EGFR-mutant lung adenocarcinoma, and its effect is not interfered with by comorbidities or mutation subtypes.
